SCHEMBL2887254

SCHEMBL2887254

COc1cc2c(cc1OC)C1CCCCC1N=C2c1ccc(OCc2ccccc2)c(OCC2CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
PDE4A P27815 6/20 0.40
PDE4D Q08499 6/20 0.40
PDE4B Q07343 5/20 0.40
PDE4C Q08493 5/20 0.40
TSHR P16473 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HSD17B10 Q99714 3/20 0.39
KDM4E B2RXH2 2/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
IGF1R P08069 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
PKM P14618 1/20 0.39
MAPT P10636 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
APP P05067 2/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2887247 1.00 C5AR1 (0.41) C5AR1PDE4APDE4DPDE4BPDE4C
SCHEMBL2887250 1.00 C5AR1 (0.41) C5AR1PDE4APDE4DPDE4BPDE4C
SCHEMBL2888181 0.93 PDE4A (0.44) PDE4APDE4DPDE4BPDE4CTSHR
SCHEMBL5743705 0.93 PDE4A (0.44) PDE4APDE4DPDE4BPDE4CTSHR
SCHEMBL2888178 0.93 PDE4A (0.44) PDE4APDE4DPDE4BPDE4CTSHR
SCHEMBL2887241 0.92 PDE4D (0.45) PDE4APDE4DPDE4BPDE4CMEN1
SCHEMBL2887239 0.92 PDE4D (0.45) PDE4APDE4DPDE4BPDE4CMEN1
SCHEMBL2887238 0.92 PDE4D (0.45) PDE4APDE4DPDE4BPDE4CMEN1
SCHEMBL2881663 0.90 PDE4D (0.46) PDE4APDE4DPDE4BPDE4CMEN1
SCHEMBL2881657 0.90 PDE4D (0.46) PDE4APDE4DPDE4BPDE4CMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776893-B2 Use of PDE4 inhibitors for the treatment of diabetes mellitus NYCOMED GMBH (DE) 2010-08-17 US disclosed
US-20060281745-A1 Use of pde4 inhibitors for the treatment of diabetes mellitus ALTANA PHARMA AG (DE) 2006-12-14 US disclosed
EP-1650193-A2 6-Phenylphenanthridines with PDE-IV inhibiting activity ALTANA Pharma AG (DE) 2006-04-26 EP disclosed
WO-2005023253-A1 USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS ALTANA PHARMA AG (DE) 2005-03-17 WO disclosed
US-6476025-B1 Phenylphennanthridines with PDE-IV inhibiting activity ALTANA PHARMA AG (DE) 2002-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281745-A1 Use of pde4 inhibitors for the treatment of diabetes mellitus PDE4A, PDE4B, PDE12 C5AR1 4067/4885PDE4A 1/4885PDE4D 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.